Trial Outcomes & Findings for Role of Bone in Knee Osteoarthritis (OA) (NCT NCT00850538)
NCT ID: NCT00850538
Last Updated: 2015-12-04
Results Overview
Recruitment status
COMPLETED
Target enrollment
101 participants
Primary outcome timeframe
Tissue samples collected at time of surgery
Results posted on
2015-12-04
Participant Flow
Participants were recruited from 4 orthopedic surgeons at one hospital between the dates of March, 2009 and April, 2013.
Participant milestones
| Measure |
Enrolled
Inclusion Criteria:
\- subjects having primary knee replacement surgery
Exclusion Criteria:
* having a revision knee replacement instead of a primary knee replacement
* contraindicated for MRI or CT scans
* allergy to the contrast agent gadolinium
* pregnant women
|
|---|---|
|
Overall Study
STARTED
|
101
|
|
Overall Study
COMPLETED
|
60
|
|
Overall Study
NOT COMPLETED
|
41
|
Reasons for withdrawal
| Measure |
Enrolled
Inclusion Criteria:
\- subjects having primary knee replacement surgery
Exclusion Criteria:
* having a revision knee replacement instead of a primary knee replacement
* contraindicated for MRI or CT scans
* allergy to the contrast agent gadolinium
* pregnant women
|
|---|---|
|
Overall Study
unable/unwilling to complete MRI
|
13
|
|
Overall Study
specimen missed due to scheduling error
|
14
|
|
Overall Study
specimen unusable
|
7
|
|
Overall Study
Withdrawal by Subject
|
3
|
|
Overall Study
radiology error
|
2
|
|
Overall Study
Protocol Violation
|
2
|
Baseline Characteristics
Role of Bone in Knee Osteoarthritis (OA)
Baseline characteristics by cohort
| Measure |
Enrolled
n=101 Participants
Subjects having primary knee replacement surgery
Exclusion Criteria:
* having a revision knee replacement instead of a primary knee replacement
* contraindicated for MRI or CT scans
* allergy to the contrast agent gadolinium
* pregnant women
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
55 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
46 Participants
n=5 Participants
|
|
Age, Continuous
|
63.89 years
STANDARD_DEVIATION 8.59 • n=5 Participants
|
|
Sex: Female, Male
Female
|
50 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
51 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
101 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Tissue samples collected at time of surgeryOutcome measures
| Measure |
Specimens
n=60 Participants
Viable specimens for genetic analysis
|
|---|---|
|
Number of Participants With Viable Specimens for Genetic Analysis
|
14 participants
|
Adverse Events
Enrolled
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place